Cipla USAdrugHigh PriorityActive

Cinacalcet Hydrochloride Manufacturing Recall

Cinacalcet Hydrochloride Tablets, 30 mg, , , Inc., 10 Ind has been recalled due to cgmp deviations: the presence of a nitrosamine impurity, n-nitroso-cinacalcet, above the acceptable daily intake (adi) limits.. Patients taking this medication should consult their pharmacist or doctor.

By RecallRadar Editorial Team

Sourced from FDA. Last verified March 4, 2026.

On this page

Free checker

Check if you qualify

See whether your device may qualify for a free repair or replacement program before you spend money.

Check if you qualify

Key facts

Date announced
November 14, 2025
Source agency
FDA

This recall involves safety concerns. Take action promptly.

Plain-English Summary

Cinacalcet Hydrochloride Tablets, 30 mg, , , Inc., 10 Ind has been recalled due to cgmp deviations: the presence of a nitrosamine impurity, n-nitroso-cinacalcet, above the acceptable daily intake (adi) limits.. Patients taking this medication should consult their pharmacist or doctor.

Is This Recall Still Active?

Status: Yes - Active

This recall is currently active. If your device matches the affected models, follow the official instructions as soon as possible.

What's Being Recalled

Quoted source excerpt from the official notice.

CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

Quick Info

Key facts from the official notice, kept in the article flow for easy cross-checking.

Brand
Cipla usa
Category
drug
Source agency
FDA
Announced
November 14, 2025
Country
US
Status
Active

Who's Affected

Specific models and identifiers listed in the source notice:

Model #1

Lot, expiry: Lot 4PB0109, exp 1/31/2026; Lot 5PB0172, exp 1/31/2027

Technical model codes are manufacturer identifiers. Match both the product name and model code from your device settings, label, or packaging.

What You Should Do

Follow the remedy path from the official notice using the exact model and serial details above.

  1. 1## Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ
  2. 2NDC: 69097-410-02 Agency: FDA | Category: drug Reason: CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits. What to do:
  3. 3Stop using the product if your lot/model matches.
  4. 4Check the FDA notice for specifics.
Open Official Recall Notice

Source & Verification

This page summarizes the official notice and keeps key facts easy to verify.

Official source
FDA
Announced by source
November 14, 2025
Last reviewed by RecallRadar
March 4, 2026

Frequently Asked Questions

Am I affected by this recall?

Check the affected models section on this page. The official notice currently lists Lot, expiry: Lot 4PB0109, exp 1/31/2026; Lot 5PB0172, exp 1/31/2027.

What is the remedy for this recall?

## Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-410-02 Agency: FDA | Category: drug Reason: CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits. What to do: 1. Stop using the product if your lot/model matches. 2. Check the FDA notice for specifics. 3. Follow remedy instructions.

Where can I verify recall details?

Use the official source link in this page to confirm dates, eligibility, and next steps: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts

Keep browsing with these internal hubs: Cipla USA recall hub and Food & Drug recall hub.

Official Resources

Use these primary sources for final eligibility and claim instructions.

View official notice from FDA

See an inaccuracy?

Help us improve the accuracy of this recall information.

500 characters remaining